Today: 7 July 2026
Browse Category

NASDAQ:AGIO 19 November 2025 - 7 July 2026

Agios Pharmaceuticals (NASDAQ:AGIO) pops as FDA review moves price above average target

Agios Pharmaceuticals (NASDAQ:AGIO) pops as FDA review moves price above average target

Agios Pharmaceuticals soared Tuesday after the FDA granted its sickle-cell disease application priority review. Shares pushed through the average Wall Street price target before any official FDA decision. Agios traded at $42.95, 9.2% higher than Google Finance’s $39.33 average 12-month target. Shares were also 34.2% over RBC Capital’s $32 target, which TradingView, via The Fly, said RBC just raised from $28. BofA has a $46 target, leaving about 7.1% upside.
7 July 2026
··
Agios Pharmaceuticals (AGIO) Stock Slides on Mixed Phase 3 Sickle Cell Results From RISE UP Trial

Agios Pharmaceuticals (AGIO) Stock Slides on Mixed Phase 3 Sickle Cell Results From RISE UP Trial

Agios Pharmaceuticals, Inc. is in the spotlight today after unveiling topline results from its pivotal Phase 3 RISE UP trial of mitapivat in sickle cell disease — data that are being widely described as “mixed” and have sent the stock sharply lower. GlobeNewswire+2Reuters+2 The study hit one of its two primary endpoints and showed strong effects on markers of hemolysis, but it failed to significantly reduce painful sickle cell crises or fatigue across the full study population — the outcomes many investors were most focused on. GlobeNewswire+2Reuters+2
19 November 2025
··

Stock Market Today

  • BMO Stock Trades Near Intrinsic Value as Australia Deal Advances
    July 7, 2026, 4:00 PM EDT. Bank of Montreal (TSX:BMO) has returned 143.9% to investors over five years. Shares now trade close to where models put its fair value. The bank's move to buy Euroz Hartleys Group's capital markets business in Australia could help long-term profit, especially in metals and mining. BMO's P/E ratio sits at 18.9, higher than peer averages, suggesting a premium valuation. The Excess Returns model puts intrinsic value at about CA$254 per share, right around current prices. The market seems to have priced in both steady fundamentals and the new deal. Investors will be watching for shifts in the economic outlook and profit forecasts that could drive valuation changes.
Go toTop